(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

ONCOREVEAL

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

ONCOREVEAL

ST13

US500000090532971

Class

35, 42, 44

Filing

90532971

Registration

7634070

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

66

Latest update

12/31/2024

Trademark type

Word

Nice classes

35, 42, 44

Filing date

02/17/2021

Registration date

12/31/2024

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

12/31/2024

Last transaction

12/31/2024

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Filing basis

Intent to use

First use anywhere

03/16/2022

First use in commerce

03/16/2022

Drawing code

4

Owner type

03

Owner location

Natick, MA

Examiner

CLYBURN, CARLA DIONNE

Law office

M10

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

Pillar Biosciences, Inc.

Representatives

Andrew T. Pettit PERKINS COIE LLP

Technical classification

Nice Classes

Class 35Class 42Class 44

Vienna Codes

No Vienna codes available.

Goods and services

Class 35

Data processing services for medicalclinicalscientific purposes

Class 42

Software as a service (SaaS)hosting non-downloadable computer software for use by others for collectingmanaginganalyzing data in the fields of scientific researchclinical researchscientific diagnosticsmedical diagnostics; software as a service (SaaS)hosting non-downloadable computer software for use by others for analyzing biological samples; software as a service (SaaS)hosting non-downloadable computer software for use by others for analyzing biological samples for medical purposesfor the diagnosis and treatment of cancer; software as a service (SaaS)hosting non-downloadable computer software for use by others with reagents and reagent kitsall for the purpose of detectingsequencinganalyzing nucleic acids and other biological moleculessamples of biological moleculesgenesgenomesnucleotide sequence variants and modificationsall in the fields of scientific researchclinical researchscientific diagnostics researchmedical diagnostics; software as a service (SaaS)hosting non-downloadable computer software for use by others for bioinformatics and gene expression microarray image analysisgene expression quantificationgene image processinggene information processing; software as a service (SaaS)hosting non-downloadable computer software for health and wellness assessmentfor genomic analysis; software as a service (SaaS)hosting non-downloadable computer software for genetic and bioinformatics analysis; bioinformatics servicesproduct research and development in the field of bioinformatics; data processing services for medicalclinicalscientific purposes; developing diagnostic testing models for others for medicalclinicalscientific purposes; Genetic testing for scientific research purposes; Scientific consulting relating to scientific research

Class 44

Providing biological sample testing services for others in the field of medical diagnostics; providing biological sample testing services for others for medical purposesfor the diagnosis and treatment of cancer; providing reagent sample testing and diagnostic services for othersdetectingsequencinganalyzing nucleic acids and other biological moleculessamples of biological moleculesgenesgenomesnucleotide sequence variants and modificationsall in the field of medical diagnostics; genetic testing for medical and clinical medical purposes; medical testing for diagnostic and treatment purposes; consulting services for medical and clinical medical purposeshealth and wellness assessment services; providing health and wellness information

Publications

History of USPTO decisions and trademark events.

66 publications found

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

12/31/2024

R.PR

REGISTERED-PRINCIPAL REGISTER

12/31/2024

SUNA

NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

10/25/2024

CNPR

ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

10/25/2024

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

09/09/2024

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

09/09/2024

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

09/06/2024

XELG

APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED

06/04/2024

XELR

APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED

06/04/2024

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

03/08/2024

GNRT

NON-FINAL ACTION E-MAILED

03/08/2024

CNRT

SU - NON-FINAL ACTION - WRITTEN

03/08/2024

DPCC

DIVISIONAL PROCESSING COMPLETE

02/06/2024

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

02/06/2024

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

01/31/2024

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

01/31/2024

DRRR

DIVISIONAL REQUEST RECEIVED

01/30/2024

ERTD

TEAS REQUEST TO DIVIDE RECEIVED

01/30/2024

XELG

APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED

10/30/2023

XELR

APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED

10/30/2023

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

07/31/2023

GNRT

NON-FINAL ACTION E-MAILED

07/31/2023

CNRT

SU - NON-FINAL ACTION - WRITTEN

07/31/2023

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

07/07/2023

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

07/07/2023

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

07/07/2023

ALIE

ASSIGNED TO LIE

07/07/2023

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

03/08/2023

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

03/08/2023

EWAF

TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS

03/08/2023

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

03/08/2023

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

03/08/2023

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

09/08/2022

GNRT

NON-FINAL ACTION E-MAILED

09/08/2022

CNRT

SU - NON-FINAL ACTION - WRITTEN

09/08/2022

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

08/11/2022

SUPC

STATEMENT OF USE PROCESSING COMPLETE

08/10/2022

EX1G

SOU EXTENSION 1 GRANTED

08/10/2022

AITU

CASE ASSIGNED TO INTENT TO USE PARALEGAL

08/10/2022

IUAF

USE AMENDMENT FILED

08/01/2022

EXT1

SOU EXTENSION 1 FILED

08/01/2022

EEXT

SOU TEAS EXTENSION RECEIVED

08/01/2022

EISU

TEAS STATEMENT OF USE RECEIVED

08/01/2022

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

02/01/2022

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

12/07/2021

PUBO

PUBLISHED FOR OPPOSITION

12/07/2021

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

11/17/2021

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

11/01/2021

XAEC

EXAMINER'S AMENDMENT ENTERED

11/01/2021

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

11/01/2021

GNEA

EXAMINERS AMENDMENT E-MAILED

11/01/2021

CNEA

EXAMINERS AMENDMENT -WRITTEN

11/01/2021

ZZZX

PREVIOUS ALLOWANCE COUNT WITHDRAWN

10/29/2021

PBCR

WITHDRAWN FROM PUB - OG REVIEW QUERY

10/19/2021

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

10/07/2021

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

10/01/2021

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

09/30/2021

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

09/30/2021

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

09/21/2021

GNRT

NON-FINAL ACTION E-MAILED

09/21/2021

CNRT

NON-FINAL ACTION WRITTEN

09/21/2021

DOCK

ASSIGNED TO EXAMINER

09/11/2021

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

05/21/2021

TAEA

TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED

02/23/2021

PARI

TEAS VOLUNTARY AMENDMENT RECEIVED

02/23/2021

NWAP

NEW APPLICATION ENTERED

02/20/2021

Continuous trademark protection

Get notified about every new filing that threatens ONCOREVEAL or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.